The upcoming sessions at the Phoenix Convention Center will focus on data that could redefine therapeutic approaches for heart failure. Among the most anticipated disclosures are results from the Cycle-1 REF and Cycle-2 PEF trials, which investigate the potential for a novel oral therapy to serve as a foundational treatment for both reduced and preserved ejection fraction heart failure. Attendees will also see first-of-its-kind imaging data intended to identify cardiac amyloidosis without the need for invasive biopsies.

Beyond pharmacology, the meeting addresses the integration of technology in patient care. The agenda includes real-world outcomes for cardiac contractility modulation and baroreflex activation therapies. Furthermore, the ACACIA-HCM trial will provide global efficacy results for aficamten in non-obstructive hypertrophic cardiomyopathy. Given the density of high-quality submissions this year, organizers have implemented rapid-fire oral sessions to ensure that these evolving clinical insights reach the medical community efficiently.